Recently, our company officially signed a commercialization consulting agreement with IQVIA Management Consulting (Shanghai) Co., Ltd. (hereinafter referred to as “IQVIA”) for the recombinant human hepatocyte growth factor naked plasmid injection (code-named NL003). Guided by the principles of complementary strengths and mutual development, the two parties will engage in in-depth collaboration on the research of NL003’s commercialization strategy.

NL003 is NORTHLAND’s core project—and also the company’s first product poised for commercial launch—has prompted the company to kick off preparations for the commercialization of NL003 at the beginning of the year, in conjunction with its clinical trial plan, to gain a comprehensive understanding of the market environment and shorten the product’s time-to-market. After examining and researching numerous domestic and international consulting firms, the company ultimately decided to partner with IQVIA for commercialization, conducting a thorough study of both the product and the market. Taking into account various market factors—including the product’s value positioning—the company proactively planned and formulated a commercialization strategy for NL003, laying a solid foundation for its smooth entry into the market.

As one of the world’s leading providers of healthcare data and clinical research services, IQVIA boasts extensive industry data assets and possesses a pioneering team and resource advantages in the field of real-world studies. Since entering the Chinese market, IQVIA has accumulated rich project experience and developed unique market analysis capabilities and insights. As early as 2019, NORTHLAND signed a strategic agreement with Quntuo Xincheng Pharmaceutical R&D (Beijing) Co., Ltd., a subsidiary of IQVIA, and took the lead in closely collaborating on the Phase III clinical study of the NL003 project. The signing of this new agreement represents another upgrade in the cooperation between the two parties. Both sides will fully leverage their respective strengths, collaborate sincerely, and work together to achieve the successful launch of China’s first naked-plasmid gene therapy drug.

About IQVIA

IQVIA is a global leader in providing advanced analytics, technology solutions, and clinical research services focused on the life sciences. Leveraging deep analytics, cutting-edge technologies, vast big data resources, and extensive domain expertise, IQVIA intelligently connects all segments of the healthcare ecosystem, delivering rapid and insightful data-driven intelligence to its clients. This enables clients to accelerate the clinical development and commercialization of innovative medical solutions, ultimately benefiting patients with improved health outcomes. IQVIA has approximately 82,000 employees and operates in more than 100 countries and regions.